Clinical efficacy and pregnancy outcomes of doxycycline plus medroxyprogesterone acetate therapy for chronic endometritis in women with recurrent reproductive failure: a prospective cohort study
Fei Yang, Dongrui Peng, Chen Wang, Xin Yang, Lijie Wang, Yaolong Chen, Fang Wang · 2026
Read Clinical efficacy and pregnancy outcomes of doxycycline plus medroxyprogesterone acetate therapy for chronic endometritis in women with recurrent reproductive failure: a prospective cohort study by Fei Yang, Dongrui Peng, Chen Wang, Xin Yang, Lijie Wang, Yaolong Chen, Fang Wang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13645782.txt.
Description
Fei Yang and six colleagues compare two antibiotic-based treatments for chronic inflammation of the womb lining in women who have had repeated reproductive failure. The condition, chronic endometritis, is diagnosed here by a tissue marker test. Their forward-looking cohort held 330 women, split evenly between doxycycline alone and doxycycline plus a hormone drug called medroxyprogesterone acetate. The main measure was whether one course cleared the inflammation on tissue testing.
Cure rates were somewhat higher with the added hormone, yet the gap was too small to rule out chance. Pregnancy, though, was clearly more common in the combined group, while side effects were mild and equal in both groups. The authors read the pattern carefully: the hormone may aid conception without clearly curing the underlying inflammation. They offer the regimen as an option worth weighing for women in this difficult situation.
Catalog record
| CREATOR | Fei Yang, Dongrui Peng, Chen Wang, Xin Yang, Lijie Wang, Yaolong Chen, Fang Wang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 28 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |